How a Clinical Trial Registry Became a Symbol of Misinformation

Hastings Center Report

Volumn 43, Issue 6, 2013, Pages 11-12

  Miller, Jennifer E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER REGISTRY; CLINICAL TRIAL (TOPIC); DRUG INDUSTRY; ETHICS; HUMAN; LEGAL ASPECT; METHODOLOGY; POLITICS; REGISTER; SCIENTIFIC MISCONDUCT; STATISTICAL BIAS; UNITED STATES; LEGISLATION AND JURISPRUDENCE;

BIAS (EPIDEMIOLOGY); CLINICAL TRIALS AS TOPIC; DRUG INDUSTRY; HUMANS; POLITICS; REGISTRIES; RESEARCH DESIGN; SCIENTIFIC MISCONDUCT; SEER PROGRAM; UNITED STATES;

EID: 84888032693     PISSN: 00930334     EISSN: 1552146X     Source Type: Journal    
DOI: 10.1002/hast.226     Document Type: Article

References (25)

1. N. E. Davidson, "Waging War on Cancer, " The Lancet 377 (2011): 801.
2. K. Dickersin and D. Rennie, "Registering Clinical Trials, " Journal of the American Medical Association 290 (2003): 516-23.
3. K. Dickersin and D. Rennie, "Registering Clinical Trials, " Journal of the American Medical Association 290 (2003): 516-23.
4. J. B. McKinlay, "From 'Promising Report' to 'Standard Procedure': Seven Stages in the Career of a Medical Innovation, " The Milbank Quarterly 59, no. 3 (1981): 374-411
5. S. Mathieu and I. Boutron, "Comparison of Registered and Published Primary Outcomes in Randomized Controlled Trials, " Journal of the American Medical Association 302 (2009): 977-84
6. K. Dickersin et al., "Publication Bias and Clinical Trials, " Controlled Clinical Trials 8 (1987): 343-53
7. C. B. Begg and J. A. Berlin, "Publication Bias: A Problem in Interpreting Medical Data, " Statistics in Society 151, no. 3 (1988): 419-63
8. E. H. Turner et al., "Selective Publication of Antidepressant Trials and Its Influence on Apparent Effcacy, " New England Journal of Medicine 358 (2008): 252-60
9. J. S. Ross et al., "Trial Publication after Registration in ClinicalTrials.Gov: A Cross-Sectional Analysis, " PLoS Med 6, no. 9 (2009).
10. B. Lo and M. J. Field, eds., Conflict of Interest in Medical Research, Education, and Practice (Washington, D.C.: Institute of Medicine, 2009), 97.
11. K. Lee, P. Bacchetti, and I. Sim, "Publication of Clinical Trials Supporting Successful New Drug Applications: A Literature Analysis, " PLoS Med 5, no. 9 (2008).
12. S. Vedantam, "FDA Told U.S. Drug System Is Broken, " Washington Post, September 23, 2006; R. J. Simes, "Publication Bias: The Case for an International Registry of Clinical Trials, " Journal of Clinical Oncology 4, no. 10 (1986): 1529-41.
13. Dickersin and Rennie, "Registering Clinical Trials."
14. Pub. L. No. 105-115, 113 Stat. 2296.
15. 42 U.S.C. § 282(j)(2)(c); ClinicalTrials. gov, "FDAAA 801 Requirements, " accessed october 9, 2013, http://clinicaltrials.gov/ct2/manage-recs/fdaaa.
16. K. Dickersin and I. Chalmers, "Recognising, Investigating and Dealing with Incomplete and Biased Reporting of Clinical Research: From Francis Bacon to the World Health organisation, " James Lind Library, www.jameslindlibrary.org, 2010
17. C. Whit-tington et al., "Selective Serotonin Reuptake Inhibitors in Childhood Depression: Systematic Review of Published versus Unpublished Data, " The Lancet 363 (2004): 1341-45.
18. A. Bass, Side Effects: A Prosecutor, a Whistleblower, and a Bestselling Antidepressant on Trial (New York: Workman Publishing, 2008)
19. J.E. Miller, "From Bad Pharma to Good Pharma: Aligning Market Forces with Good and Trustworthy Practices through Accreditation, Certification, and Rating, " Journal of Law, Medicine & Ethics 41, no. 3 (2013): 601-10.
20. The industry had started its own wholly controlled registry in the mid-2000s, but participation was voluntary. PhRMA, "Principles on Conduct of Clinical Trials and Communication of Clinical Trial Results, " october 1, 2009, http://www.phrma.org/principles-and-guidelines-clinical-trials.
21. S. Mathieu and I. Boutron, "Comparison of Registered and Published Primary outcomes in Randomized Controlled Trials, " Journal of the American Medical Association 302 (2009): 977-84.
22. M. Angell, "Industry-Sponsored Clinical Research: A Broken System, " Journal of the American Medical Association 300, no. 9 (2008): 1069-71;
23. E. Silverstein et al., "Gastrointestinal Toxicity with Celecoxib vs. Nonsteroidal Anti-Infammatory Drugs for osteoarthritis and Rheumatoid Arthritis: The CLASS Study: A Randomized Controlled Trial. Celecoxib Long-Term Arthritis Safety Study, " Journal of the American Medical Association 284, no. 10 (2000): 1247-55
24. Lo and Field, Conflict of Interest in Medical Research, Education, and Practice.
25. J. E. Miller, "Bioethical Accreditation or Rating Needed to Restore Trust in Pharma, " Nature Medicine 19 (2013): 261.